Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

GSK-2857914

Generic Name: GSK-2857914

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease

Phase 1

Recruiting

Posted: 2024/05/14

Sponsor:GlaxoSmithKline

ID:NCT06413511

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

Phase 1

Recruiting

Posted: 2023/02/06

Sponsor:GlaxoSmithKline

ID:NCT05714839

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Belantamab Mafodotin Plus VRd Shows Promising Efficacy in Newly Diagnosed Multiple Myeloma

8 months ago

The GEM-BELA-VRD trial showed a 94% objective response rate with belantamab mafodotin plus VRd in transplant-eligible, newly diagnosed multiple myeloma patients.

EHA 2024: Monoclonal Antibodies Show Promise in Multiple Myeloma Treatment

a year ago

The DREAMM-8 trial demonstrated that Blenrep combined with pomalidomide and dexamethasone significantly improved progression-free survival in relapsed/refractory multiple myeloma (RRMM) patients compared to pomalidomide, bortezomib, and dexamethasone.

Cilta-cel Demonstrates Promising Results in Early and Late Relapsed Multiple Myeloma

2 years ago

Cilta-cel shows efficacy in patients with multiple myeloma who relapsed within 12 months of frontline therapy, a population with poor prognosis.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy